Introduction
Major ABOincompatibility between donor and recipient red blood cells exists in approximately 10%to 20%of HLAmatched bone marrow transplantation (BMT) and in 15% to 20% ofHLA-mismatched BMT ( 1 ) . In ABO-mismatched BMT, double filtration plasma pheresis (DFPP) or immunoadsorption using columns containing synthetic A or B antigens has been used successfully to remove anti-A or anti-B antibodies (ab) prior to marrow infusion (2, 3) . However, the efficacy of blood apheresis for delayed red blood cell (RBC) recovery after ABOmismatched BMThas not been documented well. Wereport here two cases of leukemiawhoweretreated effectively with apheresis for persistent red cell aplasia after ABO-mismatched BMT.
Methods

Measurement of ABOantibodies
The IgM anti-A ab titer was measured by saline agglutination of major ABO-typespecific red blood cells at room temperature. Heparinized plasma was clotted by the addition of protamine sulfate before testing. Blood chemistry and hematologic values were determined at the clinical laboratories with standard techniques.
Apheresis therapy
DFPPprocedure
The patient's blood was drawn and separated into corpuscles and plasma via the first separator fiber (Plasmacure, 0.6 m2, Kuraray Co., Ltd., Osaka). The separated plasma was then passed through a second filter which was madeofethylene vinyl alcohol (Evaflax 2A, Kuraray Co.). The total volume of separated plasma was 60 ml/kg for each treatment. The filtered plasma and separated blood cells were circuited back into the patient. A saline solution containing albumin replaced the drained plasma.
Immunoadsorption procedure Immunoadsorptionwas also performed using the DFPP system, but the second filter was replaced with an immunoadsorbent (Biosynsorb A, KawasumiLaboratories, Tokyo) which was a chemically synthesized human bloodgroup substance covalently linked to crystalline silica. The volume of separated plasma was 60 ml/kg for each treatment. immunoadsorption, then to 1 :2 following these apheresis therapies on day 147, and was undetectable on day 187. Marked reticulocytosis occurred on day 20 after apheresis. The hemoglobin level increased from 6.8 g/dl to 9.9 g/dl on day 225 ( Fig. 1 ). The patient tolerated the DFPP and immunoadsorption quite well and had no complications during or after apheresis.
Patient 2
A 49-year-old female (ABO group O), who presented with a fever and petechiae was diagnosed as having acute myelogenous leukemia (AML, M2) in November 1993. A complete remission was obtained following induction chemotherapy with enocitabine (BHAC), daunorubicin (DNR) and 6-mercaptopurine (6-MP) followed by three courses of consolidation therapy with mitoxantrone (Mit), cytarabine (Ara-C), BHAC, etoposide (ET) and aclarubicin (ACR). Although her AML relapsed in May1994, the second remission was obtained after chemotherapy with Mit, ET, CYand prednisolone (PSL) (MEAP). After two additional courses of MEAPand BHAC-ACR-DMP(DNR, 6-MP, PSL) therapy, she underwent BMT from her mother whose blood type was A in December 1994. There was only one locus mismatch between the recipient and donor HLA. Mixed lymphocyte culture (MLC) was non-reactive. Before BMTshe was conditioned with4 mg/kg ofbusulfan daily for 4 days followed by CY, 60 mg/kg IV daily for two days and 2.5 mg/kg of rabbit anti-thymocyte globulin daily for four days. Her anti-A ab titer was 1:32. She received cyclosporin 3 mg/kg IV in two divided daily doses from day-1. The patient achieved early engraftment of the marrow graft that was documented by rapid recovery of WBCand platelet counts. There was no evidence of acute GVHD and hemolysis such as elevated serum indirect bilirubin or LDH levels and decreased haptoglobin levels. However, reticulocytes did not appear even 100 days after BMT. hemoglobin level increased from 6.8 g/dl to 9.4 g/dl on day 216. She tolerated the DFPPwell and manifested no complication during or after the procedures. In association with the improvement of anemia, WBCand platelet counts also increased after the last DFPP (Fig. 2) .
Comments
Recipients ofa majorABO-mismatched marrow graft do not usually experience graft rejection (4), suggesting that hematopoietic stem cells do not seem to express appreciable amounts of cell surface ABOantigens (5). However, major ABO-incompatible transplants do carry the risk of a hemolytic transfusion reaction at the time of marrowinfusion, due to the presence of incompatible donor RBCcontained in the marrow inoculum. In addition, RBCprecursors derived from the donor's stem cells may be lyzed by persistent host's anti-A or B ab, leading to the delay in the elevation of donor's RBC following BMT. Sniecinski et al (6) reported that 7.6% of patients undergoing ABO-mismatched BMTshowed markedly delayed reticulocytosis requiring 170 days or more after BMT. The present cases did not showevidence of reticulocytosis at 100 days after BMT,probably because of high titers of anti-A ab. Fukuda et al (7) Day after BMT Figure 2 . Clinical course of patient 2. After two courses ofDFPPfollowed by one course ofmethylprednisolone pulse therapy (1,000 mg daily for consecutive three days), reticulocytosis immediately occurred in association with a decrease of IgManti-A titers. Platelet and leukocyte counts also increased after these treatments.
apheresis therapy is useful not only for the prevention of both hemolysis and delayed RBCrecovery, but also for the treatment of prolonged red cell aplasia in ABO-mismatched BMT.
In most ABO-mismatchedBMT,the donor RBCsemerge in the peripheral blood within about one month after BMTand isohemagglutinin disappears from the serum due to its absorption by donor-derived RBC. Since the prevalence of delayed RBCrecovery after ABO-mismatchedBMThas been reported in about 20% (6), it is more useful to do the apheresis therapy after BMT for the case with a high isohemagglutinin titer or prolonged RBCrecovery than doing it for all cases before BMT in point of fact. Sniecinski et al (6) reported a case of prolonged red cell aplasia that was remitted 605 days after BMTfollowing 13 plasma exchanges. Similarly, in patient 2, the first three sessions of DFPPfailed to recover erythropoiesis, leading to rebound of anti-A ab titers. However, DFPP combined with methylprednisolone pulse therapy successfully reduced anti-A ab titers. It has been reported that steroid pulse therapy is useful for suppressing the rebound of antibody production after apheresis therapy ( 1 1). These findings suggest that corticosteroid therapy suppressed further production of isohemagglutinin by the residual host B cells and synergistically reduced the anti-A ab titers with DFPP. It is generally believed that the persistence of host-derived antibody-producing cells contributes to high titers of isohemagglutinin after BMT(4, 6). Non-TBI regimens used for preconditioning of our two patients may have favored the survival of host B cells, leading to the persistence of high anti-A ab titers. The combination of methylprednisolone pulse therapy with plasmapheresis may be useful for some cases with antibody-mediated red cell aplasia refractory to apheresis therapy.
Wetreated patient 1 with immunoadsorption followed by
DFPPfor delayed RBCrecovery since we were not able to repeat immunoadsorptiondue to the extensive cost of the procedure. DFPPis generally thought to be more effective than immunoadsorption in the removal of antibodies from the blood. However, immunoadsorption has advantages over DFPPin selectivity for the removal of pathogenic antibodies and in the necessity for replacement of removed plasma. In patient 1 one round of immunoadsorption greatly reduced the anti-A ab titer. Thus, immunoadsorption maybe more recommendedthan DFPPfor the treatment of prolonged red cell aplasia.
Conclusion
Immunoadsorptionand DFPPare useful in treating prolonged antibody-mediated red cell aplasia after major ABOmismatched BMT.
